Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial
Wade L. Thorstad(Washington University in St. Louis), D. Adkins(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Jingxia Liu(Washington University in St. Louis), Patrik Pipkorn(Washington University in St. Louis), José P. Zevallos(University of Pittsburgh Medical Center), Brianne Thomeczek(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), S. Puram(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis)
International Journal of Radiation Oncology*Biology*Physics
March 14, 2024
Cited by 5
Related Papers
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
|Clinical Cancer Research|2020|372
High-Risk Human Papillomavirus E6/E7 mRNA Detection by a Novel In Situ Hybridization Assay Strongly Correlates With p16 Expression and Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma
|The American Journal of Surgical Pathology|2011|292
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
|The Lancet Oncology|2021|257
The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year
|Supportive Care in Cancer|2013|176